ATE253912T1 - Verwendung von nikotinergen acetylcholinrezeptor- agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca - Google Patents

Verwendung von nikotinergen acetylcholinrezeptor- agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca

Info

Publication number
ATE253912T1
ATE253912T1 AT01927298T AT01927298T ATE253912T1 AT E253912 T1 ATE253912 T1 AT E253912T1 AT 01927298 T AT01927298 T AT 01927298T AT 01927298 T AT01927298 T AT 01927298T AT E253912 T1 ATE253912 T1 AT E253912T1
Authority
AT
Austria
Prior art keywords
medication
producing
treatment
receptor agonists
acetylcholine receptor
Prior art date
Application number
AT01927298T
Other languages
English (en)
Inventor
Benjamin R Yerxa
Ward M Peterson
Mathew Cowlen
Original Assignee
Inspire Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals filed Critical Inspire Pharmaceuticals
Application granted granted Critical
Publication of ATE253912T1 publication Critical patent/ATE253912T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01927298T 2000-04-21 2001-04-19 Verwendung von nikotinergen acetylcholinrezeptor- agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca ATE253912T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/557,059 US6277855B1 (en) 2000-04-21 2000-04-21 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists
PCT/US2001/013034 WO2001080844A2 (en) 2000-04-21 2001-04-19 Method of treating dry eye disease with nicotinic acetylcholine receptor agonists

Publications (1)

Publication Number Publication Date
ATE253912T1 true ATE253912T1 (de) 2003-11-15

Family

ID=24223897

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01927298T ATE253912T1 (de) 2000-04-21 2001-04-19 Verwendung von nikotinergen acetylcholinrezeptor- agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca

Country Status (8)

Country Link
US (1) US6277855B1 (de)
EP (1) EP1214062B1 (de)
JP (1) JP2003531168A (de)
AR (1) AR028026A1 (de)
AT (1) ATE253912T1 (de)
AU (1) AU2001253765A1 (de)
DE (1) DE60101201D1 (de)
WO (1) WO2001080844A2 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078391B2 (en) * 1997-02-10 2006-07-18 Inspire Pharmaceuticals, Inc. Method of treating edematous retinal disorders
US6596725B2 (en) * 1997-02-10 2003-07-22 Inspire Pharmaceuticals, Inc. Use of certain dinucleotides to stimulate removal of fluid in retinal detachment and retinal edema
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
US6818629B2 (en) 1997-02-10 2004-11-16 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising P1-(2'-deoxycytidine 5'-)P4-(uridine 5'-) tetraphosphate
US6455554B1 (en) * 1999-06-07 2002-09-24 Targacept, Inc. Oxopyridinyl pharmaceutical compositions and methods for use
US6576224B1 (en) * 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
US20020061281A1 (en) * 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US6596740B2 (en) * 2000-10-24 2003-07-22 Richard L. Jones Nicotine mucosal spray
GB2381750A (en) * 2001-10-10 2003-05-14 Inspire Pharmaceuticals Inc Treatment for enhancing joint lubrication
US6852741B2 (en) 2001-12-31 2005-02-08 University Of Florida Compositions and methods for treatment of neurological disorders
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7069084B2 (en) * 2002-06-14 2006-06-27 Seefit Incorporated Method and apparatus for preventing and treating eyelid problems
US7074812B2 (en) * 2002-08-02 2006-07-11 Nutraleutical Development Corporation Development of muscle mass in a mammal
US7179481B2 (en) * 2002-09-19 2007-02-20 Kimberly-Clark Worldwide, Inc. Vaginal health products
MXPA05004121A (es) * 2002-10-18 2006-02-17 Molichem Medicines Inc Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
MXPA05004866A (es) * 2002-11-08 2005-11-04 Mclean Hospital Corp Compuestos para el tratamiento de la dependencia y la abstinencia de tabaco.
US7098189B2 (en) * 2002-12-16 2006-08-29 Kimberly-Clark Worldwide, Inc. Wound and skin care compositions
US7056889B2 (en) 2002-12-16 2006-06-06 Kimberly-Clark, Worldwide, Inc. Compounds that bind P2Y2 or P2Y1 receptors
CA2508995A1 (en) * 2002-12-20 2004-07-15 The Mclean Hospital Corporation Use of cytidine-, creatine-, and adenosine-containing compounds and adenosine-elevating compounds for normalizing sleep/wake cycle, treating a sleep disorder or improving cognitive function
KR20050092429A (ko) 2003-01-22 2005-09-21 니찌방 가부시기가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
US20050013806A1 (en) * 2003-04-04 2005-01-20 Chang Min S. Use of contact lens for corneal cell transplant
US20050208102A1 (en) * 2003-04-09 2005-09-22 Schultz Clyde L Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US9216106B2 (en) * 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
US20050255144A1 (en) * 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
WO2005034874A2 (en) * 2003-10-08 2005-04-21 The Mclean Hospital Corporation Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
JP2007508315A (ja) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
AU2003296968A1 (en) * 2003-12-12 2005-07-14 Richard W. Yee Method and apparatus for preventing and treating eyelid problems
US20060270592A1 (en) * 2004-03-19 2006-11-30 Ophthalmic Research Associates, Inc. Use of neurotransmitters and neuropeptides for the treatment of dry eye diseases and related conditions
US7326683B2 (en) * 2004-05-06 2008-02-05 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
US7479481B2 (en) * 2004-05-06 2009-01-20 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
CN1819846A (zh) * 2004-05-21 2006-08-16 千寿制药株式会社 包含毒蕈碱性受体激动剂的经皮肤吸收的眼用制剂
WO2005118582A1 (ja) 2004-06-03 2005-12-15 Senju Pharmaceutical Co., Ltd. アミド化合物を含有する角膜知覚回復剤
EP1765364A4 (de) * 2004-06-10 2010-09-22 Mclean Hospital Corp Pyrimidine, wie z:b: cytidin, bei der behandlung von patienten mit bipolaren störungen
US7737128B2 (en) * 2004-06-10 2010-06-15 The Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
US7485666B2 (en) * 2004-06-17 2009-02-03 Kimberly-Clark Worldwide, Inc. Vaginal health products
WO2006020703A1 (en) * 2004-08-11 2006-02-23 The Mclean Hospital Corporation Compounds for the treatment of marihuana dependence, withdrawal, and usage
US20080233053A1 (en) * 2005-02-07 2008-09-25 Pharmalight Inc. Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients
US20090082381A1 (en) * 2005-07-26 2009-03-26 Akiharu Isowaki Percutaneously Absorbable Ophthalmic Preparation
FR2889847B1 (fr) 2005-08-18 2007-10-05 Sanofi Aventis Sa Derives de 5-pyridazinyl-1-azabicyclo[3.2.1]octave, leur preparation en therapeutique.
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
CN101316602B (zh) 2005-09-27 2015-06-03 组织技术公司 羊膜制品和纯化的组合物及其使用方法
US9726673B2 (en) 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
US20070237797A1 (en) * 2006-03-28 2007-10-11 Gholam A. Peyman Neural Conduit Agent Dissemination
US20070231360A1 (en) * 2006-03-28 2007-10-04 Minu, L.L.C. Neural conduit agent dissemination
US20070297991A1 (en) * 2006-06-23 2007-12-27 Minu, L.L.C. Neural conduit agent dissemination for smoking cessation and other applications
US20080107713A1 (en) * 2006-11-08 2008-05-08 Orilla Werhner C Contact lens as a sustained drug delivery implant
US20080317819A1 (en) * 2007-06-21 2008-12-25 Orilla Werhner C Iop lowering drug combination or non-combination loaded contact lens with zonal drug delivery areas
US20090004244A1 (en) * 2007-06-27 2009-01-01 Orilla Werhner C Iris design as a drug depot for zonal drug delivery by contact lens
US20090004245A1 (en) * 2007-06-28 2009-01-01 Orilla Werhner C Use of an iris simulated layer to allow aesthetic appearance drug loaded contact lens
DE102007055046A1 (de) * 2007-11-19 2009-05-28 Fluoron Gmbh Infusionslösung
GB0724558D0 (en) * 2007-12-15 2008-01-30 Sharma Anant Optical correction
CA2740029C (en) * 2008-05-16 2016-12-20 Axis, Inc. Pharmaceutical composition for treatment of fibromyalgia
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
KR20110091501A (ko) * 2008-10-14 2011-08-11 싸이코제닉스 아이엔씨. 니코틴성 아세틸콜린 수용체 리간드 및 이들의 용도
JP2012517402A (ja) * 2009-02-11 2012-08-02 ヘグルンド、エー．エス． 禁煙を目的としたニコチンを頬側吸収するための組成物
TWI578997B (zh) 2010-06-04 2017-04-21 輝瑞疫苗有限責任公司 用於預防或治療菸鹼成癮之共軛體
US9821159B2 (en) 2010-11-16 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Stimulation devices and methods
CA2817589A1 (en) 2010-11-16 2012-05-24 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treatment of dry eye
JP6527305B2 (ja) * 2011-01-10 2019-06-05 インヴィオン， インコーポレイテッド 禁煙のためのβ−アドレナリン作動性インバースアゴニストの使用
EP2717888B1 (de) 2011-06-10 2020-09-09 Tissuetech, Inc. Verfahren zur verarbeitung fötaler gewebesubstrate
CN103874762A (zh) 2011-08-26 2014-06-18 组织技术公司 胎儿支持组织的灭菌方法
US9132193B2 (en) 2012-11-05 2015-09-15 University of Pittsburgh—of the Commonwealth System of Higher Education Use of Slurp1 as an imunomodulatory molecule in the ocular surface
RU2510701C1 (ru) * 2012-12-19 2014-04-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт глазных болезней" Российской академии медицинских наук (ФГБУ "НИИГБ" РАМН) Способ лечения блефароконъюнктивальной формы синдрома сухого глаза
WO2014138709A1 (en) * 2013-03-08 2014-09-12 Oculeve, Inc. Devices and methods for treating dry eye in animals
US9717627B2 (en) 2013-03-12 2017-08-01 Oculeve, Inc. Implant delivery devices, systems, and methods
EP2986339A4 (de) 2013-04-19 2016-12-21 Oculeve Inc Nasenstimulationsvorrichtungen und -verfahren
JP6604963B2 (ja) 2014-02-25 2019-11-20 オキュリーブ， インコーポレイテッド 鼻涙腺刺激のためのポリマー配合物
US9303013B2 (en) 2014-05-16 2016-04-05 Pfizer Inc. Conjugates and associated methods of producing them for the prevention or treatment of nicotine addiction
CA2956176A1 (en) 2014-07-25 2016-01-28 Oculeve, Inc. Stimulation patterns for treating dry eye
EP3848028B9 (de) * 2014-10-20 2024-10-16 Oyster Point Pharma, Inc. Verfahren zur behandlung von augenleiden
US10207108B2 (en) 2014-10-22 2019-02-19 Oculeve, Inc. Implantable nasal stimulator systems and methods
JP6735742B2 (ja) 2014-10-22 2020-08-05 オキュリーブ， インコーポレイテッド ドライアイの治療のための刺激装置及び方法
AU2015335772B2 (en) 2014-10-22 2020-07-09 Oculeve, Inc. Contact lens for increasing tear production
CN107073044A (zh) * 2014-11-05 2017-08-18 组织技术公司 用于促进神经生长及再生的组合物和方法
CN107530189B (zh) 2014-12-31 2021-06-22 迈克罗欧普提克斯股份有限公司 青光眼治疗装置和方法
JP6785796B2 (ja) * 2015-05-21 2020-11-18 オフタルミ モナコＯｐｈｔａｌｍｉｓ Ｍｏｎａｃｏ 浸透圧保護剤としてのリポ酸およびタウリンの組み合わせ
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
US10980667B2 (en) 2015-09-30 2021-04-20 Microoptx Inc. Eye treatment devices and methods
US10426958B2 (en) 2015-12-04 2019-10-01 Oculeve, Inc. Intranasal stimulation for enhanced release of ocular mucins and other tear proteins
US10252048B2 (en) 2016-02-19 2019-04-09 Oculeve, Inc. Nasal stimulation for rhinitis, nasal congestion, and ocular allergies
DK3439661T3 (da) * 2016-04-07 2021-10-18 Oyster Point Pharma Inc Fremgangsmåder til behandling af øjenlidelser
KR102199560B1 (ko) 2016-04-12 2021-01-07 아르투로 솔리스 헤레라 니코틴성 아세틸콜린 수용체 작용제로 부비점막 질환을 치료하기 위한 조성물 및 방법
US10918864B2 (en) 2016-05-02 2021-02-16 Oculeve, Inc. Intranasal stimulation for treatment of meibomian gland disease and blepharitis
RU2019118600A (ru) 2016-12-02 2021-01-11 Окулив, Инк. Аппарат и способ составления прогноза синдрома сухого глаза и рекомендаций по лечению
TW202019424A (zh) * 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
WO2023279162A1 (en) * 2021-07-07 2023-01-12 University Of Canberra Methods of treatment and inhibition
DE102023208057A1 (de) * 2023-08-23 2025-02-27 Ursapharm Arzneimittel Gmbh Ophthalmologische zusammensetzung enthaltend mindestens einen nikotinischen acetylcholinrezeptor-agonist zur topischen applikation am auge bei der prävention oder behandlung von entzündungen am auge

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753945A (en) 1986-02-19 1988-06-28 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with phosphodiesterase inhibitors
US4868154A (en) 1986-02-19 1989-09-19 Eye Research Institute Of Retina Foundation Stimulation of tear secretion with melanocyte stimulating hormones
AU674541B2 (en) 1992-08-31 1997-01-02 University Of Florida Research Foundation, Inc. Anabaseine derivatives useful in the treatment of degenerative diseases of the nervous system
US5817679A (en) 1993-04-01 1998-10-06 University Of Virginia 7-Azabicyclo 2.2.1!-heptane and -heptene derivatives as cholinergic receptor ligands
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5696166A (en) * 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
DE19626373A1 (de) * 1996-07-02 1998-01-08 Boehringer Ingelheim Kg Neuartige Verwendung von Wirkstoffen, welche die Funktion von nichtneuronalem Acetylcholin beeinflussen
US5830904A (en) 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US5861423A (en) 1997-02-21 1999-01-19 Caldwell; William Scott Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds

Also Published As

Publication number Publication date
EP1214062B1 (de) 2003-11-12
AU2001253765A1 (en) 2001-11-07
EP1214062A2 (de) 2002-06-19
WO2001080844A2 (en) 2001-11-01
WO2001080844A3 (en) 2002-03-28
JP2003531168A (ja) 2003-10-21
AR028026A1 (es) 2003-04-23
DE60101201D1 (de) 2003-12-18
US6277855B1 (en) 2001-08-21

Similar Documents

Publication Publication Date Title
DE60101201D1 (de) Verwendung von nikotinergen acetylcholinrezeptor-agonisten zur herstellung eines medikaments zur behandlung von keratoconjuctivitis sicca
ATE361058T1 (de) Tablette und verfahren zur herstellung derselben
DE50206657D1 (de) Pharmazeutische zusammensetzung zur behandlung von multiple sklerose
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
DE60139256D1 (de) Verfahren und vorrichtung zur herstellung von flüssigen verabreichungsformen
EP1294410A4 (de) Verfahren und zusammensetzung zum reinigen von medizinischen geräten
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
CY2012032I1 (el) Ενωσεις 1,2-διυδροπυριδινης, διεργασια για την παρασκευη των ιδιων και χρηση εξ αυτων
ATE320803T1 (de) Verfahren zur behandlung von alzheimerschen krankheit
DE60045394D1 (de) Zusammensetzungen gegen infektionen zur behandlung erkrankten gewebes wie z.b. fieberbläschen
EE200200470A (et) Uued ühendid, meetod nende valmistamiseks ning nende kasutamine
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
ATE388135T1 (de) Verfahren zur herstellung von 1,3-substituierte indene und aryl-annellierte azapolycyclische verbindungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE69809284D1 (de) Immunomodulator mit anti-mikrobakteriellen und anti-mykobakteriellen eigenschaften, verfahren zu seiner herstellung und pharmazeutische zusammensetzungen zur behandlung von mykobakteriosen sowie von chronischen und nicht-spezifischen lungenzuständen, sexuell übertragbaren krankheiten und den daraus resultierenden immunschwächen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE59914712D1 (de) Verwendung von inhibitoren des kqt1-kanals zur herstellung eines medikaments zur behandlung von krankheiten, die durch helminthen und ektoparasiten hervorgerufen werden
ATE290366T1 (de) Pharmazeutische formulierung mit überdecktem geschmack und verfahren zu ihrer herstellung
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE59912246D1 (de) Ferroelektrischer transistor und verfahren zu dessen herstellung
ATE234617T1 (de) Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression
EE200200697A (et) Uued ühendid, meetod nende valmistamiseks ning nende kasutamine
DE50007390D1 (de) Doppel-gate-mosfet-transistor und verfahren zu seiner herstellung
ATE299371T1 (de) Antikonvulsiva zur behandlung von autismus
DE60003550D1 (de) Substituierte 3-pyridyl-4-arylpyrrole und deren einsatz in verfahren zur therapeutischen und prophylaktischen behandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties